TP53 and neoplasm: Although tumor mutation burden (TMB) has been identified a positive predictive biomarker for better response to immunotherapy [27], there was no significant difference across subgroups based on TP53 status (Fig. 4a), which indicated that the predictive value of TP53 status might be independent of TMB.